We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Information for pregnant women with singleton (having only one baby) and twin pregnancies who have received a higher-chance result from the combined or quadruple screening test
Check the tariff classification for preparations put up for retail sale.
Product Safety Report for El Paradis Cosmetic Nature Secrete A L'Huile D'Argan presenting a serious chemical risk.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine etrasimod (Velsipity) to treat people with moderately to severely active ulcerative colitis.
Product Safety Report for Fabrique par Rodis B.B.Clear Lightening Dark Spot Remover presenting a serious chemical risk.
FCDO travel advice for Nicaragua. Includes safety and security, insurance, entry requirements and legal differences.
Explains control of advertisement regime.
Product Safety Report for LA LA LA Huile Eclaircissante 100ml Skin Lightening Oil sold via eBay presenting a serious chemical risk.
FCDO travel advice for Spain. Includes safety and security, insurance, entry requirements and legal differences.
How to get state healthcare when you’re on holiday or travelling to Spain.
Healthcare professionals prescribing montelukast should be alert to the risk of neuropsychiatric reactions in all patients including children and adolescents. Reported neuropsychiatric reactions include sleep disorders, hallucinations, anxiety and depression, as well as changes in behaviour and mood. Healthcare professionals...
STFYAYB provides information about the screening tests offered during and after pregnancy.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
A. Menarini Farmaceutica Internazionale Srl is recalling a specific batch as a precautionary measure due to the distribution of Invokana 300mg in Northern Ireland in packaging intended for the Greek market.
The CMA investigated alleged excessive and unfair pricing, anti-competitive agreements and abusive conduct with respect to hydrocortisone tablets under Chapters I and II CA98 and Articles 101 and 102 TFEU.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).